Iovance Biotherapeutics downgraded by UBS with a new price target
$IOVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2025 | $2.00 | Buy → Neutral | UBS |
| 5/12/2025 | Buy → Hold | Truist | |
| 5/9/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 10/24/2024 | $17.00 | Buy | UBS |
| 7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
| 11/20/2023 | $12.00 | Buy | Goldman |
| 9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
| 5/30/2023 | $11.00 → $17.00 | Equal Weight → Overweight | Wells Fargo |
UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00
Truist downgraded Iovance Biotherapeutics from Buy to Hold
Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform
For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)